Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection

PHASE3CompletedINTERVENTIONAL

Enrollment

107

Participants

Timeline

Start Date

July 1, 2015

Primary Completion Date

April 29, 2016

Study Completion Date

June 22, 2016

Conditions

Hepatitis C Virus Infection

Interventions

DRUG

SOF/VEL

400/100 mg fixed-dose combination (FDC) tablet administered orally once daily

Trial Locations (15)

Birmingham

Los Angeles

San Diego

San Francisco

Torrance

Atlanta

Chicago

Baltimore

Lutherville

Boston

New York

The Bronx

Durham

Cincinnati

Richmond